SETD1Aの非触媒作用は,細胞サイクルにおけるE2F4-TAF6軸を通じた胃がん細胞の増殖を促進する
Meng Ning1, Takayuki Hoshii2, Takuya Nakagawa3,4
1Department of Molecular Oncology, Graduate School of Medicine, Chiba University, Chiba-shi, Japan.
Cell death & disease
|August 22, 2025
まとめ
SETD1Aの非触媒FLOSドメインは,胃がん (GC) 細胞増殖に不可欠であり,TAF6とE2F4を介して細胞サイクル進行を調節する. この発見は,GCの新たな治療目標を示しています.
科学分野:
- 腫瘍学
- 分子生物学
- 細胞生物学
背景:
- ヒストンメチルトランスフェラーゼであるSETD1Aは,胃がん (GC) の不良予後に関連しています.
- 異常なSETD1A発現は,GC進行における重要な要因である.
研究 の 目的:
- GC細胞増殖におけるSETD1Aの役割を調査する.
- GCでSETD1Aによって規制される下流経路を特定する.
主な方法:
- CRISPRスクリーニングとcDNA救出実験が採用されました.
- E2F標的遺伝子を含む遺伝子発現の分析が行われました.
- GC患者のデータにおけるSETD1A,TAF6,E2F4mRNA発現の相関分析
主要な成果:
- SETD1Aの非触媒FLOSドメインは,触媒ドメインではないが,GC細胞増殖に不可欠である.
- SETD1Aの喪失は,GCサブタイプにおけるE2F標的遺伝子発現を減少させる.
- TAF6はSETD1Aの非触媒的機能の後方に作用し,GC細胞の増殖に不可欠です.
- SETD1AとTAF6は,G1/S細胞サイクル進行のために必要である.
- E2F4の発現は,SETD1AとTAF6と相関し,TAF6発現をサポートする同調剤として作用する.
結論:
- SETD1Aは,非正規の機能を通してGC細胞サイクル進行において重要な役割を果たします.
- SETD1A-TAF6-E2F4経路は,GC細胞増殖を維持するために不可欠です.
- SETD1Aの非触媒的機能またはその下流エフェクターをターゲットにすることで,GCに対する新しい治療戦略を提供することができます.
関連する概念動画
02:38Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
03:03mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
8.0K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.0K
01:23Negative Regulator Molecules
35.9K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.9K
02:34Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K